Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention.
Jadwiga ManiewskaDagmara JeżewskaPublished in: Cancers (2021)
Since colorectal cancer is one of the world's most common cancers, studies on its prevention and early diagnosis are an emerging area of clinical oncology these days. For this study, a review of randomized controlled, double-blind clinical trials of selected NSAIDs (aspirin, sulindac and celecoxib) in chemoprevention of colorectal cancer was conducted. The main molecular anticancer activity of NSAIDs is thought to be a suppression of prostaglandin E2 synthesis via cyclooxygenase-2 inhibition, which causes a decrease in tumor cell proliferation, angiogenesis, and increases apoptosis. The lower incidence of colorectal cancer in the NSAID patients suggests the long-lasting chemopreventive effect of drugs studied. This new approach to therapy of colorectal cancer may transform the disease from a terminal to a chronic one that can be taken under control.
Keyphrases
- anti inflammatory drugs
- clinical trial
- double blind
- cell proliferation
- placebo controlled
- end stage renal disease
- newly diagnosed
- low dose
- phase iii
- ejection fraction
- randomized controlled trial
- open label
- prognostic factors
- endothelial cells
- type diabetes
- risk factors
- stem cells
- study protocol
- endoplasmic reticulum stress
- cell cycle
- peritoneal dialysis
- cardiovascular events
- patient reported outcomes
- cell cycle arrest
- young adults
- childhood cancer